Strategies for active and passive pediatric RSV immunization
KM Eichinger, JL Kosanovich, M Lipp… - … in Vaccines and …, 2021 - journals.sagepub.com
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in
children worldwide, with the most severe disease occurring in very young infants. Despite …
children worldwide, with the most severe disease occurring in very young infants. Despite …
Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination
H Gu, T Li, L Han, P Zhu, P Zhang… - Human Vaccines & …, 2015 - Taylor & Francis
Respiratory syncytial virus (RSV) is a major pathogen in infants and the elderly, causing
pneumonia and bronchiolitis. Despite decades of research, to date there is still no approved …
pneumonia and bronchiolitis. Despite decades of research, to date there is still no approved …
New preventive strategies for respiratory syncytial virus infection in children
R Glowinski, A Mejias, O Ramilo - Current Opinion in Virology, 2021 - Elsevier
Respiratory syncytial virus (RSV) infections result in significant morbidity and mortality for
young children worldwide. The development of preventive strategies for RSV has faced …
young children worldwide. The development of preventive strategies for RSV has faced …
Respiratory syncytial virus immunobiology and pathogenesis
BS Graham, JA Rutigliano, TR Johnson - Virology, 2002 - Elsevier
Respiratory syncytial virus (RSV) is a pneumovirus in the family Paramyxoviridae. It is a
pleomorphic enveloped virus about 150 nm in diameter, transmitted by large particle aerosol …
pleomorphic enveloped virus about 150 nm in diameter, transmitted by large particle aerosol …
Translational sciences approach to RSV vaccine development
V Kurzweil, R Tang, M Galinski, K Wang… - Expert review of …, 2013 - Taylor & Francis
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in
infants and the elderly. Despite its relatively low degree of antigenic variation, it causes …
infants and the elderly. Despite its relatively low degree of antigenic variation, it causes …
Preventive strategies for respiratory syncytial virus infection in young infants
J Taveras, O Ramilo, A Mejias - Neoreviews, 2020 - publications.aap.org
Respiratory syncytial virus (RSV) is the leading cause of acute viral lower respiratory tract
infections in young children, with the peak of severe disease occurring in infants younger …
infections in young children, with the peak of severe disease occurring in infants younger …
Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 …
KHL Hsu, JE Crowe Jr, MD Lubeck, AR Davis… - Vaccine, 1995 - Elsevier
Ts-1, a temperature sensitive (ts) mutant of RSV, was previously derived from RSV A2 virus
by mutagenesis with 5-fluorouracil (5-FU). Ts-1 was attenuated for adult volunteers and …
by mutagenesis with 5-fluorouracil (5-FU). Ts-1 was attenuated for adult volunteers and …
Up-to-date role of biologics in the management of respiratory syncytial virus
S Boyoglu-Barnum, RA Tripp - Expert Opinion on Biological …, 2020 - Taylor & Francis
Introduction Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory
tract disease in young children and a substantial contributor to respiratory tract disease …
tract disease in young children and a substantial contributor to respiratory tract disease …
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
NI Mazur, D Higgins, MC Nunes, JA Melero… - The Lancet Infectious …, 2018 - thelancet.com
The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly
recognised, not only in infants, but also in older adults (aged≥ 65 years). Advances in …
recognised, not only in infants, but also in older adults (aged≥ 65 years). Advances in …
Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults
UF Power, TN Nguyen, E Rietveld… - The Journal of …, 2001 - academic.oup.com
A novel recombinant respiratory syncytial virus (RSV) subunit vaccine, designated BBG2Na,
was administered to 108 healthy adults randomly assigned to receive 10, 100, or 300 μg of …
was administered to 108 healthy adults randomly assigned to receive 10, 100, or 300 μg of …